Selank is a synthetic peptide derived from the naturally occurring immunomodulatory peptide tuftsin. Studied primarily in Russian clinical research, Selank has demonstrated anxiolytic and nootropic properties in both animal models and limited human trials, with a favorable safety profile and no observed dependence or sedation. Researchers investigating cognitive enhancement and stress modulation consider it one of the more well-characterized regulatory peptides in the anxiolytic space.
Selank (TP-7) is a heptapeptide that has attracted significant attention as both an anxiety-modulating and nootropic peptide in preclinical and clinical research. Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, Selank extends the sequence of the endogenous tetrapeptide tuftsin (Thr-Lys-Pro-Arg) with a Pro-Gly-Pro tail that enhances metabolic stability. This Selank anxiety and nootropic peptide guide covers the compound’s mechanism of action, studied dosing protocols, research outcomes, and practical considerations for investigators working with this peptide in controlled settings.
What Is Selank? Origin and Structure
Selank’s full amino acid sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro. The addition of the glyproline fragment to tuftsin was a deliberate design choice: tuftsin alone is rapidly degraded by aminopeptidases in vivo, giving it a plasma half-life of only minutes. The Pro-Gly-Pro extension significantly increases resistance to enzymatic breakdown, allowing the peptide to exert its effects over a more practical timeframe.
In Russia, Selank has been approved as an intranasal anxiolytic under the brand name Selanк (0.15% nasal drops). While it is not approved by the FDA or EMA for clinical use, its well-documented pharmacological profile makes it a subject of active investigation in Western peptide research communities. Selank is classified alongside other regulatory peptides such as Semax, another Russian-developed compound targeting cognitive and neuroprotective pathways.
Mechanism of Action: How Selank Works
Selank’s mechanism of action is multifaceted, involving several overlapping neurochemical and immunological pathways. Understanding these mechanisms is essential for researchers designing protocols around this compound.
GABAergic modulation: Selank has been shown to allosterically modulate GABA-A receptors, enhancing inhibitory neurotransmission without directly binding the benzodiazepine site. This distinction is critical — it suggests anxiolytic activity without the sedation, tolerance, or dependence risks associated with classical benzodiazepines. A 2009 study published in the Bulletin of Experimental Biology and Medicine demonstrated that Selank increased GABA binding by up to 40% in hippocampal preparations.
Monoamine regulation: Research indicates that Selank influences the metabolism of serotonin (5-HT), dopamine, and norepinephrine. Specifically, Selank has been observed to stabilize enkephalin degradation and modulate the balance between serotonin and its metabolites in the hypothalamus and frontal cortex, which may underlie both its anxiolytic and mood-stabilizing effects.
BDNF expression: Several studies have reported that Selank upregulates brain-derived neurotrophic factor (BDNF) expression, particularly in the hippocampus. BDNF is a key mediator of synaptic plasticity, learning, and memory consolidation — the likely mechanism behind Selank’s nootropic classification.
Immunomodulation: As a tuftsin derivative, Selank retains immunomodulatory activity. It has been shown to influence the expression of interleukin-6 (IL-6), interferon-related genes, and other cytokines, suggesting a role in balancing inflammatory and anti-inflammatory responses. This dual anxiolytic-immunomodulatory profile is relatively unique among studied peptides.
Research Outcomes: Anxiety and Cognitive Performance
The clinical and preclinical evidence for Selank spans several decades of Russian pharmacological research, with a growing body of independent investigation emerging from other institutions.
| Study / Model | Key Finding | Dosing | Route |
|---|---|---|---|
| Zozulya et al., 2008 (Human, GAD) | Comparable anxiolytic effect to medazepam with no sedation or cognitive impairment | 270 µg/day | Intranasal |
| Seredenin et al., 2009 (Animal, elevated plus maze) | Significant increase in time spent in open arms; dose-dependent anxiolysis | 100–300 µg/kg | Intranasal / IP |
| Kozlovskii & Danchev, 2003 (Animal, learning tasks) | Improved spatial memory retention and reversal learning in rats | 250–500 µg/kg | IP injection |
| Ershov et al., 2009 (Human, gene expression) | Modulated expression of 45 genes related to immune function and neurotransmission | 270 µg/day | Intranasal |
| Kost et al., 2001 (In vitro, enkephalin metabolism) | Inhibited enkephalin-degrading enzymes, prolonging endogenous opioid peptide activity | N/A (in vitro) | N/A |
Across these studies, Selank consistently demonstrates anxiolytic effects that are comparable to — or in some models superior to — classical anxiolytics, without producing sedation, withdrawal symptoms, or cognitive blunting. The nootropic effects appear most pronounced in tasks involving memory consolidation and attentional flexibility, which aligns with the observed BDNF upregulation and monoamine modulation.
Studied Dosing Protocols
The most commonly studied route of administration for Selank is intranasal, though subcutaneous injection protocols also appear in the literature. In Russian clinical use, the standard dosing is 270 µg per day administered intranasally, divided into three doses of 90 µg each, over a course of 14 days. Subcutaneous research protocols have used doses ranging from 250 to 750 µg per day, though these protocols are less standardized.
Selank’s half-life following intranasal administration is estimated at several minutes in plasma, but its downstream effects on gene expression and neurotransmitter balance persist for hours. This pharmacokinetic profile supports multiple daily administrations rather than a single bolus dose. Researchers working with subcutaneous protocols should note that precise measurement is essential, making insulin syringes the standard tool for accurate microgram-level dosing.
What You Will Need
Before beginning this protocol, researchers typically gather the following supplies: bacteriostatic water for reconstitution, insulin syringes for precise measurement, alcohol prep pads for sterile technique, and a sharps container for safe disposal. Proper peptide storage cases or a dedicated mini fridge help maintain compound integrity between uses. Selank is particularly sensitive to temperature fluctuation — once reconstituted, the solution should be refrigerated at 2–8°C and used within 3–4 weeks. Lyophilized (unreconstituted) Selank is more stable but should still be stored in a cool, dark environment to prevent degradation.
Safety Profile and Side Effects
Selank’s safety profile is one of its most notable characteristics. Across published human and animal studies, no significant adverse effects have been reported at standard research doses. Critically, Selank does not appear to produce tolerance, physical dependence, or withdrawal — a stark contrast to benzodiazepines and other GABAergic anxiolytics. The Russian Ministry of Health has classified it as having a favorable safety margin, and its LD50 in animal models has not been reached at doses hundreds of times above therapeutic ranges.
That said, as with any peptide under active investigation, long-term safety data from large, randomized Western clinical trials is limited. Researchers should approach dosing conservatively and maintain careful observation logs throughout any protocol.
Stacking Considerations: Synergistic Research Approaches
Researchers investigating cognitive optimization frequently examine Selank alongside other compounds that target complementary pathways. Selank and Semax are often studied together — Semax primarily targets the melanocortin system and BDNF through a different mechanism, potentially creating additive nootropic effects. Lion’s mane mushroom (Hericium erinaceus) is another compound of interest due to its well-documented stimulation of nerve growth factor (NGF) synthesis, which works through a pathway distinct from Selank’s BDNF modulation. The combination represents a multi-target approach to neurotrophic support.
For researchers focused on the anxiolytic dimension, ashwagandha (Withania somnifera) is frequently cited as a complementary adaptogen. Ashwagandha’s primary mechanism involves HPA axis modulation and cortisol reduction — a pathway that intersects with, but does not duplicate, Selank’s GABAergic and serotonergic activity. Additionally, magnesium glycinate is widely recognized for its role in GABA receptor function and sleep quality, making it a logical adjunct for researchers studying anxiety-related protocols where sleep disruption is a variable.
Track your peptide protocol for free
Log every dose, cost, weight change, and observation in one place. Free web app — no credit card needed.
Complementary Research Tools and Supplements
Beyond direct stacking compounds, several supportive interventions are relevant to Selank research protocols. Omega-3 fish oil supplementation has been extensively studied for its role in neuroinflammation modulation and membrane fluidity — both of which can influence peptide receptor sensitivity and overall brain health. Vitamin D3 is another commonly tracked variable, given its well-established role in immune regulation and its potential interaction with Selank’s immunomodulatory effects. Researchers monitoring stress physiology alongside Selank protocols may also benefit from cold plunge or ice bath exposure, which activates norepinephrine release and has been studied for its own anxiolytic and anti-inflammatory effects — providing a useful non-pharmacological comparator or adjunct in research design.
Where to Source
Peptide quality is a non-negotiable variable in any research protocol. When sourcing Selank, researchers should verify that the vendor provides third-party testing results and certificates of analysis (COAs) confirming peptide identity, purity (≥98%), and the absence of endotoxin contamination. EZ Peptides (ezpeptides.com) meets these criteria, offering independently verified COAs for each batch. Use code PEPSTACK for 10% off at EZ Peptides. Regardless of vendor, always review the COA before use and confirm that HPLC and mass spectrometry data match the expected molecular weight and sequence for Selank (MW ~751.9 Da).
Frequently Asked Questions
Q: How does Selank compare to benzodiazepines for anxiety research?
A: In published studies, Selank has demonstrated anxiolytic effects comparable to low-dose benzodiazepines like medazepam, but without the sedation, cognitive impairment, tolerance development, or dependence that characterize classical GABAergic drugs. Its allosteric modulation of GABA-A receptors — rather than direct agonism at the benzodiazepine binding site — is believed to account for this difference.
Q: Can Selank be administered subcutaneously instead of intranasally?
A: Yes. While intranasal administration is the most commonly studied route and the basis for the approved Russian formulation, subcutaneous injection protocols have been used in research settings. Subcutaneous delivery may offer more consistent bioavailability. When using this route, reconstitution with bacteriostatic water and proper sterile technique with alcohol prep pads are essential.
Q: How long do the nootropic effects of Selank take to become observable?
A: Anxiolytic effects have been observed within the first few administrations in human trials. Nootropic effects — particularly improvements in memory consolidation and attentional flexibility — appear to develop more gradually, with most studies reporting measurable cognitive changes after 7–14 days of consistent administration. BDNF-mediated neuroplastic changes are inherently slower processes than acute neurotransmitter modulation.
Q: Does Selank need to be cycled?
A: The standard studied protocol duration is 14 days, and there is no published evidence of tolerance developing within this timeframe. Some researchers employ an on-off cycling pattern (e.g., 14 days on, 14 days off) as a precautionary measure, though the published data does not indicate this is strictly necessary. Longer-term continuous use has not been sufficiently studied to make definitive recommendations.
This article is for research and informational purposes only. Nothing on PepStackHQ constitutes medical advice. Consult a qualified healthcare professional before beginning any research protocol.